National Practice Patterns and Outcomes for T4b Urothelial Cancer of the Bladder

被引:21
作者
Haque, Waqar [1 ]
Verma, Vivek [2 ]
Butler, E. Brian [3 ]
Teh, Bin S. [3 ]
机构
[1] Greater Houston Phys Med Assoc, Dept Radiat Oncol, Houston, TX USA
[2] Univ Nebraska Med Ctr, Dept Radiat Oncol, Omaha, NE USA
[3] Houston Methodist Hosp, Dept Radiat Oncol, Houston, TX 77030 USA
关键词
Bladder cancer; Chemoradiation; Chemotherapy; Cystectomy; Radiation therapy; RADICAL CYSTECTOMY; DATA-BASE; NEOADJUVANT CHEMOTHERAPY; PROGNOSTIC-FACTORS; SURVIVAL; CARCINOMA; CARE; THERAPY;
D O I
10.1016/j.clgc.2017.08.013
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The National Cancer Data Base was queried (2004-2013) for patients diagnosed with T4b bladder cancer. A total of 896 patients were observed. Patients treated with definitive chemoradiation or radical cystectomy were observed to have the highest overall survival. Purpose: Management of cT4b bladder cancer is poorly defined; national guidelines recommend chemotherapy (CT) alone or chemoradiation (CRT). Using a large, contemporary dataset, we evaluated national practice patterns as well as associated outcomes, especially with respect to radical cystectomy (RC) and CRT versus CT alone. Methods: The National Cancer Data Base was queried (2004-2013) for patients diagnosed with cT4bN0-3M0 bladder cancer. Patients were divided into 5 treatment groups: CT alone, CRT, RC (with/without CT/radiotherapy [RT]), other treatment (subtherapeutic RT with/without CT), or no treatment. Statistics included multivariable logistic regression to determine factors predictive of observation, Kaplan-Meier analysis to evaluate overall survival (OS), and Cox proportional hazards modeling to determine variables associated with OS. Results: Of 896 total patients, 185 (20.6%) underwent CT alone, 80 (8.9%) CRT, 161 (18.9%) RC, 221 (24.7%) other treatments, and 249 (27.8%) observation. Differences in treatment paradigms were appreciated based on age, gender, nodal status, insurance, and facility-related parameters. Observation yielded a median OS of 3.7 months, lower than CT alone (P < .001). As compared with the latter, CRT was associated with higher OS (10.5 vs. 12.1 months, P = .004). RC-based treatment displayed the numerically highest OS (14.2 months) and was statistically similar to CRT (P = .676). Treatment with any modality independently predicted for superior OS over observation. Conclusions: In the largest study of its kind, a surprisingly high proportion of patients underwent observation. CRT is associated with higher survival over CT alone, and carefully selected patients undergoing RC may experience prolonged survival. (C) 2017 Elsevier Inc. All rights reserved.
引用
收藏
页码:42 / +
页数:9
相关论文
共 50 条
  • [31] Upper Urinary Tract Urothelial Cancer After Radical Cystectomy for Bladder Cancer: Survival Outcomes After Radical Nephroureterectomy
    Slusarczyk, Aleksander
    Zapala, Piotr
    Piecha, Tomasz
    Zapala, Lukasz
    Borkowski, Tomasz
    Radziszewski, Piotr
    ANNALS OF SURGICAL ONCOLOGY, 2023, 31 (3) : 2144 - 2153
  • [32] Survival of Patients with Muscle-Invasive Urothelial Cancer of the Bladder with Residual Disease at Time of Cystectomy: A Comparative Survival Analysis of Treatment Modalities in the National Cancer Database
    Pfail, John L.
    Audenet, Francois
    Martini, Alberto
    Tomer, Nir
    Paranjpe, Ishan
    Daza, Jorge
    Attalla, Kyrollis
    Waingankar, Nikhil
    Mehrazin, Reza
    Wiklund, Peter
    Galsky, Matthew D.
    Sfakianos, John P.
    BLADDER CANCER, 2020, 6 (03) : 265 - 276
  • [33] The Patterns of Practice and Outcomes of Penile Cancer in Ontario
    Mahmud, A.
    Qu, X.
    Yip, D.
    Leveridge, M.
    Mackillop, W.
    CLINICAL ONCOLOGY, 2017, 29 (04) : 239 - 247
  • [34] Skin Involvement and Breast Cancer: Are T4b Lesions of All Sizes Created Equal?
    Silverman, Diana
    Ruth, Karen
    Sigurdson, Elin R.
    Egleston, Brian L.
    Goldstein, Lori J.
    Wong, Yu-Ning
    Boraas, Marcia
    Bleicher, Richard J.
    JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS, 2014, 219 (03) : 534 - 544
  • [35] Extended Gastrectomy for T4b Gastric Adenocarcinoma: Single-Surgeon Experience
    Sahakyan, Mushegh A.
    Gabrielyan, Artak
    Petrosyan, Hmayak
    Yesayan, Shushan
    Shahbazyan, Sevak S.
    Sahakyan, Arthur M.
    JOURNAL OF GASTROINTESTINAL CANCER, 2020, 51 (01) : 135 - 143
  • [36] Small Cell Bladder Cancer: Treatment Patterns for Local Disease and Associated Outcomes. A Retrospective Cohort Study
    Bakaloudi, Dimitra Rafailia
    Koehne, Elizabeth L.
    Diamantopoulos, Leonidas N.
    Holt, Sarah K.
    Sekar, Rishi R.
    Ghali, Fady
    Vakar-Lopez, Funda
    Nyame, Yaw A.
    Psutka, Sarah P.
    Gore, John L.
    Calle, Claire M. de la
    Lin, Daniel W.
    Schade, George R.
    Liao, Jay J.
    Hsieh, Andrew C.
    Yezefski, Todd
    Hawley, Jessica E.
    Yu, Evan Y.
    Montgomery, R. Bruce
    Grivas, Petros
    Wright, Jonathan L.
    CLINICAL GENITOURINARY CANCER, 2024, 22 (06)
  • [37] A Meta-analysis of Surgical Outcomes of T4a and Infranotch T4b Oral Cancers
    Rao, Karthik Nagaraja
    Arora, Ripudaman
    Dange, Prajwal
    Nagarkar, Nitin
    Makitie, Antti A.
    Kowalski, Luiz P.
    Eisbruch, Avraham
    Hamoir, Marc
    Civantos, Francisco J.
    Vander Poorten, Vincent
    Ng, Sweet Ping
    Nuyts, Sandra
    Zafereo, Mark
    Asarkar, Ameya A.
    Golusinski, Pawel
    Ronen, Ohad
    Ferlito, Alfio
    ONCOLOGY AND THERAPY, 2023, 11 (04) : 461 - 480
  • [38] Clinical presentation, national practice patterns, and outcomes of breast adenomyoepithelioma
    Haque, Waqar
    Verma, Vivek
    Klimberg, Vickie Suzanne
    Nangia, Julie
    Schwartz, Mary
    Butler, Edward Brian
    Teh, Bin S.
    BREAST JOURNAL, 2020, 26 (04) : 653 - 660
  • [39] Outcomes of trimodality approach in the management of T2N0M0 bladder cancer
    Uysal, Bora
    Beyzadeoglu, Murat
    Demiral, Selcuk
    Gamsiz, Hakan
    Dincoglan, Ferrat
    Sager, Omer
    Akin, Mustafa
    Babayigit, Mustafa Alparslan
    TUMORI, 2015, 101 (02) : 232 - 237
  • [40] The Prognosis of Tumors with only Microscopic Skin Involvement without Clinical T4b Signs is Significantly Better than T4b Tumors in Breast Carcinoma
    Duraker, Nuvit
    Bati, Bakir
    Caynak, Zeynep Civelek
    Demir, Davut
    Kurtulus, Idris
    BREAST JOURNAL, 2011, 17 (01) : 47 - 55